Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers

British Journal of Ophthalmology

Volumn 84, Issue 6, 2000, Pages 622-625

  Nousiainen, Iiris ^a   Kälviäinen, Reetta ^b   Mäntyjärvi, Maija ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b Department of Neurology ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; VIGABATRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; GLARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INSTRUMENTATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETINA MACULA LUTEA; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTICONVULSANTS; CARBAMAZEPINE; CONTRAST SENSITIVITY; EPILEPSIES, PARTIAL; FOLLOW-UP STUDIES; GLARE; HUMANS; MIDDLE AGED; VIGABATRIN; VISUAL ACUITY; VISUAL FIELDS;

EID: 1642586728     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.84.6.622     Document Type: Article

References (25)

1. Mattson RH. Carbamazepine. In: Engel J Jr, Pedley TA, ed. Epilepsy. A comprehensive textbook. Vol 2. Philadelphia: Lippincott-Raven, 1998:1491-502.
2. Tomson T, Nilsson BY, Levi R. Impaired visual contrast sensitivity in epileptic patients treated with carbamazepine. Arch Neurol 1988;45:897-900.
3. Bayer A, Thiel HJ, Zrenner E, et al. Farbsinnstörungen und erhöhte Blendungsempfindlichkeit unter Phenytoin-und Carbamazepintherapie. Nervenarzt 1995;66:89-96.
4. Bayer A, Theil HJ, Zrenner E, et al. Empfindliche sinnesphysiologisch Testmethoden für oculäre Nebenwirkungen von Medikamenten am Beispiel verschiedener Antiepileptika. Ophtalmologe 1995;92:182-90.
5. Perez M-TR, Davanger S. Distribution of GABA immunoreactivity in kainic acid-treated rabbit retina. Exp Brain Res 1994;100:227-38.
6. Arnarsson A, Eysteinsson T. The role of GABA in modulating the Xenopus electroretinogram. Vis Neurosci 1997;14: 1143-52.
7. Davson H. Transmitters in the retina .In: Physiology of the eye. 5th ed. London: MacMillan Press, 1990:343-52.
8. Ben-Menachem E. Vigabatrin. Epilepsia 1995;36:S95-104.
9. Kälviäinen R, Keränen T, Riekkinen PJ Sr. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993;46:1009-24.
10. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction assosiated with vigabatrin. BMJ 1997;314: 180-1.
11. Wong ICK, Mawer GE, Sander JWAS. Severe persistent visual constriction associated with vigabatrin. Reaction may be dose dependent. BMJ 1997;314:1693-4.
12. Blackwell N, Hayllar J, Kelly G. Severe persistent visual constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing. BMJ 1997;314:1694.
13. Kramer G, Scollo-Lavizzari G, Jallon P, et al. Vigabatrin-associated bilateral concentric visual field defects in four patients. Epilepsia 1997;38:179.
14. Mackenzie R, Klistorner A. Severe persistent visual constriction associated with vigabatrin. A symptomatic as well as symptomatic defects occur with vigabatrin. BMJ 1998;316:232.
15. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction. Electroretinogram and ophtalmologic findings. Neurology 1998;50:614-18.
16. Kälviäinen R, Äikiä M, Saukkonen A, et al. Vigabatrin vs carbamazepin monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995;52:989-96.
17. Sartucci F, Massetani R, Galli R, et al. Visual contrast sensitivity in carbamazepine-resistant epileptic patients receiving vigabatrin as add-on therapy. J Epilepsy 1997;10:7-11.
18. Steinhoff B, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception II. A controlled study in patients with epilepsy under long-term antiepileptic medication. Epilepsy Res 1997;29: 49-58.
19. Tiel-Wilck K, Jokiel B, Zinser P, et al. Afferent visual function after single dose application of γ-vinyl GABA. Neuroophtalmology 1995;15:305-10.
20. Steinhoff B, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double blind, single-dose study in healthy volunteers. Epilepsy Res 1997;29:35-47.
21. Kälviäinen R, Nousiainen I, Mäntyjärvi, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-6.
22. Pelli D, Robson J, Wilkins A. The design of a new letter chart for measuring contrast sensitivity. Clin Vis Sci 1988;2:187-99.
23. Rubin G. Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vis Sci 1988;2:169-77.
24. Glaser J, Savino P, Sumers K, et al. The photostress recovery test in the clinical assessment of visual function. Am J Ophthalmol 1977;83:255-60.
25. Pow DV, Baldridge W, Crook DK. Activity-dependent transport of GABA analogues into specific cell types demonstrated at high resolution using a novel immunocytochemical strategy. Neuroscience 1996;73:1129-13.